<DOC>
	<DOC>NCT00879398</DOC>
	<brief_summary>The objective of this study is to determine the problems and questions of safety and efficacy of Toviaz® under the standard conditions of usage.</brief_summary>
	<brief_title>Toviaz Post Marketing Surveillance Study</brief_title>
	<detailed_description>continuous registration method</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Subjects who are diagnosed as Overactive Bladder (OAB) defined as urgency, with or without urgency incontinence, usually with frequency and nocturia, in the absence of local or metabolic factors explaining these factors. Hypersensitivity to the active substance or to peanut or soya or any of the excipients Urinary retention Gastric retention Uncontrolled narrow angle glaucoma Myasthenia gravis Severe hepatic impairment (Child Pugh C) Concomitant use of potent CYP3A4 inhibitors in subjects with moderate to severe hepatic or renal impairment Severe ulcerative colitis Toxic megacolon Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption (Toviaz® prolongedrelease tablets contain lactose)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>